Study to Evaluate Safety and Efficacy of DB-020 to Protect Hearing in Patients Receiving Cisplatin for Cancer Treatment
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate whether DB-020 administered via an injection in the
middle ear prevents hearing loss in participants who will receive high doses of cisplatin as
part of their treatment for cancer.